<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04689035</url>
  </required_header>
  <id_info>
    <org_study_id>AVLX-144CS01</org_study_id>
    <nct_id>NCT04689035</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144</brief_title>
  <official_title>A Phase 1, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenously Administered AVLX-144</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avilex Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avilex Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, single ascending dose study in&#xD;
      healthy volunteer subjects. Each dose level will be investigated with eight 20-50-year-old&#xD;
      male subjects (6 on active drug and 2 on placebo). Additionally, eight healthy elderly&#xD;
      subjects (65-80 years of age, males and females), 6 on active drug and 2 on placebo, will be&#xD;
      included in the study at one dose level, once the safety and tolerability of AVLX-144 has&#xD;
      been documented in younger subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 27, 2020</start_date>
  <completion_date type="Anticipated">April 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of AVLX-144</measure>
    <time_frame>From randomisation to end of study participation</time_frame>
    <description>Safety and tolerability will be assessed by recording adverse events (AEs), by performing physical examinations and safety laboratory assessments (blood and urine), and by recording vital signs and electrocardiograms (ECGs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter</measure>
    <time_frame>From dosing until 48 hours after dosing</time_frame>
    <description>AUClast (the area under the plasma concentration-time curve from time zero to the last sample with a quantifiable concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter</measure>
    <time_frame>24 hrs</time_frame>
    <description>AUC0-24 (the area under the plasma concentration-time curve from time zero to 24 h),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter AUC</measure>
    <time_frame>From start to end of assessment</time_frame>
    <description>AUCinf (the area under the plasma concentration-time curve from time zero extrapolated to infinity, if feasible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameter elimination</measure>
    <time_frame>From start to end of assessment</time_frame>
    <description>elimination constant λz and t½ (terminal elimination half-life, if feasible), and systemic plasma clearance (Cl) and volume of distribution (Vd)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Safety Issues</condition>
  <condition>Tolerance</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVLX-144_dose1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVLX-144_dose2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVLX-144_dose3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVLX-144_dose4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVLX-144_dose5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVLX-144_elderly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVLX-144</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>Test drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Healthy male and female subjects, body mass index (BMI) 18-28 kg/m2, body weight from 50&#xD;
        kg (females) or 60 kg (males) up to 100 kg, good general health.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - History or evidence of current clinically significant cardiovascular, pulmonary, renal,&#xD;
        hepatic, gastrointestinal, haematological, metabolic-endocrine, neurological, urogenital or&#xD;
        psychiatric disorder. Febrile convulsions in childhood do not necessarily exclude a&#xD;
        subject, but subjects with any type of generalized seizure in adulthood must be excluded.&#xD;
        Personal or first-degree family history of congenital long QT syndrome or sudden death of a&#xD;
        first-degree relative suspected to be due to long QT syndrome will also exclude the&#xD;
        subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Scheinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Services Turku / CRST Oy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikael Thomsen, PhD</last_name>
    <phone>23276134</phone>
    <email>mik.thomsen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristian Stromgaard, PhD</last_name>
    <phone>51236114</phone>
    <email>kristian.stromgaard@avilexpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Services Turku / CRST Oy</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scheinin Scheinin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

